CN104173925A - Traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia - Google Patents
Traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia Download PDFInfo
- Publication number
- CN104173925A CN104173925A CN201410405313.5A CN201410405313A CN104173925A CN 104173925 A CN104173925 A CN 104173925A CN 201410405313 A CN201410405313 A CN 201410405313A CN 104173925 A CN104173925 A CN 104173925A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 21
- 208000027119 bilirubin metabolic disease Diseases 0.000 title abstract description 10
- 208000036796 hyperbilirubinemia Diseases 0.000 title abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 210000003038 endothelium Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 24
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 17
- 241000180649 Panax notoginseng Species 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000001054 red pigment Substances 0.000 claims description 10
- 241000180579 Arca Species 0.000 claims description 6
- 235000014375 Curcuma Nutrition 0.000 claims description 6
- 241000612166 Lysimachia Species 0.000 claims description 6
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- 201000003639 autosomal recessive cerebellar ataxia Diseases 0.000 claims description 6
- 244000164439 Curcuma angustifolia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 1
- 241000092668 Artemisia capillaris Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 235000003398 Curcuma aromatica Nutrition 0.000 abstract 1
- 241000506964 Dichondra repens Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 10
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 206010023126 Jaundice Diseases 0.000 description 6
- 241000407170 Curcuma Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and aims at providing a traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia according to a cognition mechanism of traditional Chinese medicine on the liver cirrhosis hyperbilirubinemia. The traditional Chinese medicine composition is characterized by being prepared by combining the following medicine raw materials in parts by weight: 30-60 parts of artemisia capillaris thunb, 12-20 parts of reynoutria japonica houtt, 25-35 parts of dichondra repens, 25-35 parts of endothelium corneum gigeriae galli, 12-18 parts of scutellaria baicalensis, 30-60 parts of root of common peony, 12-20 parts of curcuma aromatica, 2-10 parts of pseudo-ginseng powder, 25-35 parts of coix seeds, 25-35 parts of concha arcae, 0.5-2.5 parts of bear gall powder and 25-35 parts of processed turtle shell. The traditional Chinese medicines of the composition have the advantages of lasting medicine effect, definite treatment effect, high safety, no toxic and side effects and simple medicine administration mode.
Description
Technical field
The invention belongs to technical field of Chinese medicines, specifically refer to a kind of Chinese medicine composition for the treatment of liver cirrhosis hyperbilirubinemia.
Background technology
Liver cirrhosis is that the interior dispersivity fibrosis of liver and liver cell regeneration tuberosity make normal configuration reconstruction easily cause bilirubin metabolism, acatharsia, pathological changes complexity, and touching difficulty is more.Hyperbilirubinemia is on this basis the feature of active liver cirrhosis, and jaundice degree is the fiducial mark that judges that hepatocyte is destroyed.Present most scholar thinks that several factors can make the hepatic bile stasis of blood long-pending, causes hyperbilirubinemia, and particularly importantly hepatocyte injury, liver internal recycle obstacle, blood viscosity increase, angiotensinⅡ increases, liver submicroscopic structure changes.Doctor trained in Western medicine for the conventional therapy measure of this card is, the compensatory phase has a rest, give high heat, high protein and vitamin abundant and light food, medicine with silymarin tablet, Radix Salviae Miltiorrhizae Injection, G/W add diammonium glycyrrhizinate, vitamin C,, and G/W adds bitter yellow etc.Above-mentioned treatment measure is mainly symptomatic treatment, and its therapeutic effect is often difficult to accomplish the end in view.
Summary of the invention
The object of the invention is the understanding mechanism to liver cirrhosis hyperbilirubinemia according to motherland's medical science, a kind of Chinese medicine composition for the treatment of this disease is provided on the basis of Chinese medical discrimination.
For realizing above-mentioned technical purpose, the technical solution adopted in the present invention is: a kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: Herba Artemisiae Scopariae 30-60 part, Rhizoma Polygoni Cuspidati 12-20 part, Herba Lysimachiae 25-35 part, Endothelium Corneum Gigeriae Galli 25-35 part, Radix Scutellariae 12-18 part, Radix Paeoniae Rubra 30-60 part, Radix Curcumae 12-20 part, Radix Notoginseng powder 2-10 part, Semen Coicis 25-35 part, Concha Arcae 25-35 part, Fel Ursi powder 0.5-2.5 part, Carapax Trionycis (processed) 25-35 part.
Further, the preferred weight proportioning of above-mentioned raw materials medicine is: Herba Artemisiae Scopariae 40-50 part, Rhizoma Polygoni Cuspidati 15-18 part, Herba Lysimachiae 28-32 part, Endothelium Corneum Gigeriae Galli 28-32 part, Radix Scutellariae 14-16 part, Radix Paeoniae Rubra 35-45 part, Radix Curcumae 15-18 part, Radix Notoginseng powder 5-7 part, Semen Coicis 28-32 part, Concha Arcae 28-32 part, Fel Ursi powder 1-2 part, Carapax Trionycis (processed) 28-32 part.
Further, the optimum weight proportion of above-mentioned raw materials medicine is: 45 parts of Herba Artemisiae Scopariaes, 16 parts of Rhizoma Polygoni Cuspidati, 30 parts of Herba Lysimachiaes, 30 parts of Endothelium Corneum Gigeriae Galli, 15 parts of Radix Scutellariaes, 40 parts of Radix Paeoniae Rubra, 16 parts of Radix Curcumaes, 6 parts of Radix Notoginseng powder, 30 parts of Semen Coiciss, 30 parts of Concha Arcaes, 1.5 parts of Fel Ursi powders, 30 parts of Carapax Trionycis (processed)s.
The decoction method of said medicine is: the weight portion of above-mentioned raw materials medicine carries out fried using g as unit as a pair, decocting method is Carapax Trionycis (processed) to be put into water be decocted first, after boiling, puts in water other material medicines except Radix Notoginseng powder, Fel Ursi powder, intense fire is decocted to water and is boiled, change at a simmerly to medicine juice residue 200-300ml, filter to obtain medicine juice.Add again decocting to medicine juice and remain 200-300ml, filter to obtain medicine juice, will twice gained medicine juice add Radix Notoginseng powder and Fel Ursi powder after mixing, point sooner or later take for twice, every day one pair.
Prescription analysis: motherland's medical science is thought, liver cirrhosis hyperbilirubinemia belongs to " jaundice ", " gathering ", " tympanites " category, its morbidity cause is to cause edema with the liver involved not rise because middle scorched earth is wet and strongly fragrant, coagulation of QI-blood, Yu Sheng is damp and hot, humidifying of a specified duration is expectorant, caused by liver and kidney deficiency, and the outstanding difficultyization of the cementing expectorant stagnating it.Therefore should be taking depressed liver-energy dispersing and QI regulating, clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling, nourishing the liver and kidney as basic principle when prescription.In Chinese medicine composition provided by the present invention, get Endothelium Corneum Gigeriae Galli, Semen Coicis removing food stagnancy is stagnant, strengthening the spleen and stomach, lets out dampness, and edema with the liver involved hair growth promoting is strong for middle strong focus, get the effect of eliminating damp-heat, relieving stranguria by diuresis of Herba Artemisiae Scopariae, Rhizoma Polygoni Cuspidati, Herba Lysimachiae with jaundice eliminating, Radix Curcumae, Radix Notoginseng powder blood circulation promoting and blood stasis dispelling, the clots absorbing of dual-purpose Radix Paeoniae Rubra, the effect of pain relieving, share and more can remove gallbladder liver-fire with Radix Scutellariae, Fel Ursi powder, heat clearing away suppressing the hyperactive liver, more gets the effect of hard masses softening and resolving of Concha Arcae, Carapax Trionycis (processed) to change cementing sluggish expectorant.Said medicine is share, and plays altogether persistent erection of the penis Jiao, blood stasis dispelling and invigorate blood circulation, fill up the effect of losing of Liver and kidney, the edema with the liver involved that disappears hot and suffocating, and the hair growth promoting of short edema with the liver involved, reaches the object of this disease for the treatment of by adjusting the interior environment of human body.
Beneficial effect of the present invention: Chinese medicine of the present invention has lasting medicine, determined curative effect, safe, have no side effect and the simple advantage of medication.
Detailed description of the invention
Embodiment 1
A kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: Herba Artemisiae Scopariae 60g, Rhizoma Polygoni Cuspidati 20g, Herba Lysimachiae 35g, Endothelium Corneum Gigeriae Galli 35g, Radix Scutellariae 18g, Radix Paeoniae Rubra 60g, Radix Curcumae 20g, Radix Notoginseng powder 10g, Semen Coicis 35g, Concha Arcae 35g, Fel Ursi powder 2.5g, Carapax Trionycis (processed) 35g.
The decoction method of above-mentioned raw materials Chinese medicine is: Carapax Trionycis (processed) is put into water and be decocted first, put into other material medicines except Radix Notoginseng powder, Fel Ursi powder after water boils, intense fire is decocted to water and boiled, and changes at a simmerly to medicine juice residue 200-300ml, filters to obtain medicine juice.Add again decocting to medicine juice and remain 200-300ml, filter to obtain medicine juice, will twice gained medicine juice add Radix Notoginseng powder and Fel Ursi powder after mixing, point sooner or later take for twice, every day one pair.
In the present embodiment, for medicine is carried out to toxicity test, the weight portion of each material medicine is got its maximum weight part and is tested, and toxicity test is divided into acute toxicity testing and long term toxicity test, and result is as follows:
Acute toxicity test: for convenience of feeding that white mice is offerd medicine, Chinese medicine decoction prepared by the embodiment of the present invention 1 concentrates atomization pelletize and obtains Chinese medicinal granule.Chinese medicinal granule is dissolved in distilled water,, observes 7 to white mice dispensing feeding with 160 times of clinical consumption per day.The activity of all white mice of result, diet, hair no abnormality seen, have no toxic reaction.Irritation test is carried out in white mouse oral cavity and damaged skin, there are no irritative response and other untoward reaction.
Long term toxicity test: the Chinese medicinal granule of preparing in this embodiment of the invention is dissolved in water by 19. 32g crude drug/kg mice, to mice continuous use 12 weeks, every day 2 times, and drug withdrawal is after 2 weeks, result shows: the indexs such as the hair, behavior, defecation, body weight, organ weights, hemogram, hepatic and renal function, blood glucose, blood fat of Chinese medicine of the present invention to test white mice all have no significant effect, and internal organs naked eyes do not find that difference changes.Adopt histological examination result to show, medication 12 weeks and drug withdrawal are after 2 weeks, and Organs of Mice is all without obviously changing.
Embodiment 2
A kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: Herba Artemisiae Scopariae 45g, Rhizoma Polygoni Cuspidati 16g, Herba Lysimachiae 30g, Endothelium Corneum Gigeriae Galli 30g, Radix Scutellariae 15g, Radix Paeoniae Rubra 40g, Radix Curcumae 16g, Radix Notoginseng powder 6g, Semen Coicis 30g, Concha Arcae 30g, Fel Ursi powder 1.5g, Carapax Trionycis (processed) 30g.
In the present embodiment, adopt the material medicine of above-mentioned weight proportion to carry out clinical trial, test as follows:
Clinical data:
Case selection: fetch and come from hospital and outpatient's 36 routine liver cirrhosis hyperbilirubinemia patients, male 28 examples, female's 8 examples; 32～64 years old age, average 51 years old.36 routine patients are divided into treatment by Chinese herbs group and western medicine group at random, every group of 18 people.
Diagnostic criteria:
Therapeutic Method: matched group carries out conventional liver protecting therapy to 10% glucose injection+vitamin c+Herba Silybi mariani sheet, treatment group employing is taken Chinese medicine composition provided by the present invention and is treated, and within one month, is a course for the treatment of.
Observation index: look into total bilirubin level before and after treatment, observe effective percentage after two groups of blood total bilirubin decline difference degrees and two groups of patient treatments, wherein treating after 4 weeks blood total bilirubin, to drop to 50% before treatment be effective.
Result: total bilirubin decline degree comparison before and after two groups of treatments, treatment group is apparently higher than matched group, and after two groups of treatments, effective percentage have notable difference, the results are shown in Table 1, table 2.
Blood total bilirubin comparison (μ mol/L) before and after table 1 liang group patient treatment
| Group | Before treatment | After treatment |
| Treatment group | 378.56±21.6 | 93.85±8.6 |
| Matched group | 375.85±22.15 | 162.12±12.21 |
Table 2 liang group patient treatment effective percentage
| Group | Number of cases | Effectively number of cases | Effective percentage (%) |
| Treatment group | 18 | 15 | 83.3 |
| Matched group | 18 | 11 | 61.1 |
Untoward reaction: treatment group and matched group have no untoward reaction.
Embodiment 3
A kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: 30 parts of Herba Artemisiae Scopariaes, 20 parts of Rhizoma Polygoni Cuspidati, 25 parts of Herba Lysimachiaes, 35 parts of Endothelium Corneum Gigeriae Galli, 12 parts of Radix Scutellariaes, 60 parts of Radix Paeoniae Rubra, 12 parts of Radix Curcumaes, 10 parts of Radix Notoginseng powder, 25 parts of Semen Coiciss, 35 parts of Concha Arcaes, 0.5 part of Fel Ursi powder, 35 parts of Carapax Trionycis (processed)s.
Embodiment 4
A kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: 60 parts of Herba Artemisiae Scopariaes, 12 parts of Rhizoma Polygoni Cuspidati, 35 parts of Herba Lysimachiaes, 25 parts of Endothelium Corneum Gigeriae Galli, 18 parts of Radix Scutellariaes, 30 parts of Radix Paeoniae Rubra, 20 parts of Radix Curcumaes, 2 parts of Radix Notoginseng powder, 35 parts of Semen Coiciss, 25 parts of Concha Arcaes, 2.5 parts of Fel Ursi powders, 25 parts of Carapax Trionycis (processed)s.
Embodiment 5
A kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: 40 parts of Herba Artemisiae Scopariaes, 18 parts of Rhizoma Polygoni Cuspidati, 28 parts of Herba Lysimachiaes, 32 parts of Endothelium Corneum Gigeriae Galli, 14 parts of Radix Scutellariaes, 45 parts of Radix Paeoniae Rubra, 15 parts of Radix Curcumaes, 7 parts of Radix Notoginseng powder, 28 parts of Semen Coiciss, 32 parts of Concha Arcaes, 1 part of Fel Ursi powder, 32 parts of Carapax Trionycis (processed)s.
Embodiment 6
A kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: 50 parts of Herba Artemisiae Scopariaes, 15 parts of Rhizoma Polygoni Cuspidati, 32 parts of Herba Lysimachiaes, 28 parts of Endothelium Corneum Gigeriae Galli, 16 parts of Radix Scutellariaes, 35 parts of Radix Paeoniae Rubra, 18 parts of Radix Curcumaes, 5 parts of Radix Notoginseng powder, 32 parts of Semen Coiciss, 28 parts of Concha Arcaes, 2 parts of Fel Ursi powders, 28 parts of Carapax Trionycis (processed)s.
Model case
Lee, man, 58 years old, clinical diagnosis was liver cirrhosis, blood total bilirubin index 320.55 μ mol/L, visible jaundice.
Treatment is treated to take Chinese medicine composition provided by the present invention, and every day one, pair, sooner or later took for twice, and be a course for the treatment of January, finishes the course for the treatment of rear blood total bilirubin to be detected.
Take after January, blood total bilirubin index drops to 210.85 μ mol/L, and jaundice is improved, and takes after February, and blood total bilirubin index drops to 122.35 μ mol/L, and jaundice obviously alleviates.
Claims (3)
1. treat the Chinese medicine composition of the high red pigment mass formed by blood stasis of liver cirrhosis for one kind, it is characterized in that, this Chinese medicine composition is to be combined by the material medicine of following weight proportion: Herba Artemisiae Scopariae 30-60 part, Rhizoma Polygoni Cuspidati 12-20 part, Herba Lysimachiae 25-35 part, Endothelium Corneum Gigeriae Galli 25-35 part, Radix Scutellariae 12-18 part, Radix Paeoniae Rubra 30-60 part, Radix Curcumae 12-20 part, Radix Notoginseng powder 2-10 part, Semen Coicis 25-35 part, Concha Arcae 25-35 part, Fel Ursi powder 0.5-2.5 part, Carapax Trionycis (processed) 25-35 part.
2. a kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis according to claim 1, it is characterized in that, the preferred weight proportioning of described material medicine is: Herba Artemisiae Scopariae 40-50 part, Rhizoma Polygoni Cuspidati 15-18 part, Herba Lysimachiae 28-32 part, Endothelium Corneum Gigeriae Galli 28-32 part, Radix Scutellariae 14-16 part, Radix Paeoniae Rubra 35-45 part, Radix Curcumae 15-18 part, Radix Notoginseng powder 5-7 part, Semen Coicis 28-32 part, Concha Arcae 28-32 part, Fel Ursi powder 1-2 part, Carapax Trionycis (processed) 28-32 part.
3. a kind of Chinese medicine composition for the treatment of the high red pigment mass formed by blood stasis of liver cirrhosis according to claim 1, it is characterized in that, the optimum weight proportion of described material medicine is: 45 parts of Herba Artemisiae Scopariaes, 16 parts of Rhizoma Polygoni Cuspidati, 30 parts of Herba Lysimachiaes, 30 parts of Endothelium Corneum Gigeriae Galli, 15 parts of Radix Scutellariaes, 40 parts of Radix Paeoniae Rubra, 16 parts of Radix Curcumaes, 6 parts of Radix Notoginseng powder, 30 parts of Semen Coiciss, 30 parts of Concha Arcaes, 1.5 parts of Fel Ursi powders, 30 parts of Carapax Trionycis (processed)s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410405313.5A CN104173925A (en) | 2014-08-18 | 2014-08-18 | Traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410405313.5A CN104173925A (en) | 2014-08-18 | 2014-08-18 | Traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104173925A true CN104173925A (en) | 2014-12-03 |
Family
ID=51955452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410405313.5A Pending CN104173925A (en) | 2014-08-18 | 2014-08-18 | Traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104173925A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446544A (en) * | 2013-09-03 | 2013-12-18 | 陈柏林 | Chinese medicine pill for treating liver cirrhosis |
-
2014
- 2014-08-18 CN CN201410405313.5A patent/CN104173925A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446544A (en) * | 2013-09-03 | 2013-12-18 | 陈柏林 | Chinese medicine pill for treating liver cirrhosis |
Non-Patent Citations (2)
| Title |
|---|
| 周德生，肖志红: "《中医药方全书》", 31 August 2013 * |
| 曲波 主编: "《家用补益中药大全》", 31 January 2014 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101804166B (en) | Traditional Chinese medicine composition for treating dermatitis and eczema of infants | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN102727779B (en) | Pharmaceutical composition for treating ovarian cysts and preparation method thereof | |
| CN104491695A (en) | Pharmaceutical composition for treating chloasma | |
| CN105106758A (en) | Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness | |
| CN102114230A (en) | Medicament for treating psoriasis | |
| CN104435678A (en) | Traditional Chinese medicine composition for treating palpitation caused by qi stagnation and blood stasis syndrome | |
| CN103784768A (en) | Traditional Chinese medicine composition for treating palpitation | |
| CN102526635A (en) | Medicament for treating premenstrual stress syndrome and preparation method thereof | |
| CN104436048A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating qi stagnation and blood stasis type chloasma | |
| CN104606561A (en) | Traditional Chinese medicinal composition for treating spontaneous perspiration | |
| CN104042981A (en) | Medicament for treating postnatal constipation and preparation method thereof | |
| CN101301454B (en) | Navel plaster with powder for soothing heart | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN104225282A (en) | Traditional Chinese medicine for treating postpartum headache | |
| CN104173925A (en) | Traditional Chinese medicine composition for treating liver cirrhosis hyperbilirubinemia | |
| CN101269191A (en) | Externally applied medicament for treating hepatopathy | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN105168774A (en) | Traditional Chinese medicine preparation for treating scapulohumeral periarthritis and preparation method thereof | |
| CN105194294A (en) | Menstruation regulating and blood nourishing pill and preparation method thereof | |
| CN106075180A (en) | A kind of Chinese medicine treating intravertebral anesthesia postoperative urine retention and preparation method thereof | |
| CN105106786A (en) | Traditional Chinese medicine composition capable of dredging collaterals and relaxing muscles as well as preparation and production method of composition | |
| CN104056196A (en) | Traditional Chinese medicine composition for treating bradycardia | |
| CN104758851A (en) | Traditional Chinese medicine composition for treating stroke sequela |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141203 |
|
| RJ01 | Rejection of invention patent application after publication |